- Home
- INCY vs QXO Comparison
INCY vs QXO Comparison
Compare INCY & QXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- QXO
- Stock Information
- Founded
- INCY 1991
- QXO 1988
- Country
- INCY United States
- QXO United States
- Employees
- INCY N/A
- QXO N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- QXO EDP Services
- Sector
- INCY Health Care
- QXO Technology
- Exchange
- INCY Nasdaq
- QXO Nasdaq
- Market Cap
- INCY 17.0B
- QXO 13.2B
- IPO Year
- INCY 1993
- QXO N/A
- Fundamental
- Price
- INCY $105.22
- QXO $17.16
- Analyst Decision
- INCY Buy
- QXO Strong Buy
- Analyst Count
- INCY 19
- QXO 12
- Target Price
- INCY $89.19
- QXO $33.45
- AVG Volume (30 Days)
- INCY 2.8M
- QXO 7.9M
- Earning Date
- INCY 10-28-2025
- QXO 11-06-2025
- Dividend Yield
- INCY N/A
- QXO N/A
- EPS Growth
- INCY 3878.02
- QXO N/A
- EPS
- INCY 5.90
- QXO N/A
- Revenue
- INCY $4,813,105,000.00
- QXO $4,662,873,000.00
- Revenue This Year
- INCY $19.33
- QXO $12,779.57
- Revenue Next Year
- INCY $10.47
- QXO $56.23
- P/E Ratio
- INCY $17.95
- QXO N/A
- Revenue Growth
- INCY 18.09
- QXO 8107.98
- 52 Week Low
- INCY $53.56
- QXO $11.85
- 52 Week High
- INCY $106.47
- QXO $24.69
- Technical
- Relative Strength Index (RSI)
- INCY 79.03
- QXO 39.90
- Support Level
- INCY $91.16
- QXO $17.64
- Resistance Level
- INCY $106.47
- QXO $18.85
- Average True Range (ATR)
- INCY 4.10
- QXO 0.82
- MACD
- INCY 1.59
- QXO -0.14
- Stochastic Oscillator
- INCY 94.41
- QXO 36.90
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About QXO QXO Inc. Common Stock
QXO Inc is a building products distribution company engaged in the distribution of roofing, waterproofing and complementary building products in North America. It offers a full suite of business applications, including ERP, warehouse management, accounting, CRM, and business intelligence solutions.